Simbec Research has announced the appointment of Prof Trevor M Jones CBE as non-executive Chairman of the Board of Directors. Prof Jones was formerly Group R&D Director of Wellcome and Director General of the Association of the British Pharmaceutical Industry (ABPI).
Prof Jones joins the Board following the recent acquisition of the Company through investment from the Wales Life Sciences Investment Fund (WLSIF) along with Prof Sir Chris Evans and Simbec’s executive Directors Howard Jenkins and Dr Trevor Tanner.
Prof Sir Chris Evans, from Arthurian and Chairman of the Welsh Life Sciences Hub said “We are delighted that Prof Trevor Jones has agreed to be the new Chairman of Simbec Research which has a proven successful track record over 30 years in providing key clinical research expertise to global and UK based pharmaceutical and biotech companies. Prof Jones brings to the Board his wide, international understanding of pharmaceutical and biotech R&D and proven leadership skills.”
Prof Jones is well known internationally for his activities in clinical research and drug discovery and development in the pharmaceutical industry. He has served on many Committees including the UK Government Medicines Commission, Chair of the UK Genetics Advisory Board, the Council of King’s College London an as a Commissioner at The World Health Organisation (WHO). He commented: “It is a great pleasure to be joining Simbec with its established reputation for excellence in the efficient conduct of clinical trials for regulatory approvals.”